Redox-responsive branched-bottlebrush polymers for \u3ci\u3ein vivo\u3c/i\u3e MRI and fluorescence imaging by Sowers, Molly A. et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Andrzej Rajca Publications Published Research - Department of Chemistry
2014
Redox-responsive branched-bottlebrush polymers
for in vivo MRI and fluorescence imaging
Molly A. Sowers
Massachusetts Institute of Technology
Jessica R. McCombs
Massachusetts Institute of Technology
Ying Wang
University of Nebraska-Lincoln
Joseph T. Paletta
University of Nebraska-Lincoln
Stephen W. Morton
Massachusetts Institute of Technology
See next page for additional authors
Follow this and additional works at: http://digitalcommons.unl.edu/chemistryrajca
This Article is brought to you for free and open access by the Published Research - Department of Chemistry at DigitalCommons@University of
Nebraska - Lincoln. It has been accepted for inclusion in Andrzej Rajca Publications by an authorized administrator of DigitalCommons@University of
Nebraska - Lincoln.
Sowers, Molly A.; McCombs, Jessica R.; Wang, Ying; Paletta, Joseph T.; Morton, Stephen W.; Dreaden, Erik C.; Boska, Michael D.;
Ottaviani, M. Francesca; Hammond, Paula T.; Rajca, Andrzej; and Johnson, Jeremiah A., "Redox-responsive branched-bottlebrush
polymers for in vivo MRI and fluorescence imaging" (2014). Andrzej Rajca Publications. 12.
http://digitalcommons.unl.edu/chemistryrajca/12
Authors
Molly A. Sowers, Jessica R. McCombs, Ying Wang, Joseph T. Paletta, Stephen W. Morton, Erik C. Dreaden,
Michael D. Boska, M. Francesca Ottaviani, Paula T. Hammond, Andrzej Rajca, and Jeremiah A. Johnson
This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/chemistryrajca/12
Redox-responsive branched-bottlebrush polymers for in vivo 
MRI and fluorescence imaging
Molly A. Sowers1, Jessica R. McCombs1, Ying Wang2, Joseph T. Paletta2, Stephen W. 
Morton3, Erik C. Dreaden3, Michael D. Boska4, M. Francesca Ottaviani5, Paula T. 
Hammond3, Andrzej Rajca2, and Jeremiah A. Johnson1
1Department of Chemistry, Massachusetts Institute of Technology, 77 Massachusetts Avenue, 
Cambridge, Massachusetts 02139, USA.
2Department of Chemistry, University of Nebraska, Lincoln, Nebraska 68588, USA.
3Department of Chemical Engineering, Koch Institute for Integrative Cancer Research, Institute 
for Soldier Nanotechnologies, Massachusetts Institute of Technology, 77 Massachusetts Avenue, 
Cambridge, Massachusetts 02139, USA.
4Department of Radiology, University of Nebraska Medical Center, Omaha, Nebraska 68198.
5Department of Earth, Life and Environmental Sciences, University of Urbino, Loc. Corcicchia, 
61029 Urbino, Italy.
Abstract
Stimuli-responsive multimodality imaging agents have broad potential in medical diagnostics. 
Herein, we report the development of a new class of branched-bottlebrush polymer dual-modality 
organic radical contrast agents—ORCAFluors—for combined magnetic resonance and near-
infrared fluorescence imaging in vivo. These nitroxide radical-based nanostructures have 
longitudinal and transverse relaxation times that are on par with commonly used heavy-metal-
based magnetic resonance imaging (MRI) contrast agents. Furthermore, these materials display a 
unique compensatory redox response: fluorescence is partially quenched by surrounding 
nitroxides in the native state; exposure to ascorbate or ascorbate/glutathione leads to nitroxide 
reduction and a concomitant 2- to 3.5-fold increase in fluorescence emission. This behaviour 
enables correlation of MRI contrast, fluorescence intensity and spin concentration with tissues 
known to possess high concentrations of ascorbate in mice. Our in vitro and in vivo results, along 
with our modular synthetic approach, make ORCAFluors a promising new platform for 
multimodality molecular imaging.
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Nanoparticle (NP)-based multimodality imaging agents have broad potential for applications 
in medical diagnostics1–3. Of the common modalities, magnetic resonance imaging (MRI) 
and optical imaging are particularly common in clinical and research laboratories: MRI is 
used to image millions of patients per year4,5, while near-infrared (NIR) optical imaging is 
emerging as a powerful tool for image-guided surgery6, and is used routinely to monitor 
disease progression and nanoparticle biodistribution in animal models7,8.
There are several reports of small molecule9–13 and NP14–21-based constructs for combined 
MRI and fluorescence imaging. In some cases, these agents are stimuli-responsive ‘sensors’ 
that feature enhanced contrast or emission in response to specific cellular signals22. For 
example, Zn(II)9,10, Cu(II)11,12, NADH13 and pH19,20-responsive dual-modality MRI/
fluorescent agents have been designed. Though these systems have provided useful insights 
into biochemical processes, they are often limited to in vitro imaging studies; the 
fluorophores used do not absorb/emit in the NIR, which is necessary for in vivo optical 
imaging. Furthermore, these systems invariably rely on the use of paramagnetic metals to 
achieve MRI contrast via alteration of the nuclear relaxation times of endogenous 
protons23,24. Though widely used in both research and clinical applications, metal-based 
MRI contrast agents face toxicity concerns4,23,25,26; metal-free MRI/NIR agents could 
provide a safer alternative for dual-modality in vivo imaging.
Recently, Thurecht and coworkers reported a novel hyper-branched polymer NP construct 
for simultaneous in vivo 19F-MRI and NIR optical imaging21. Though this elegant system 
avoids metals, it requires the use of 19F-MRI, which is not yet commonplace in the clinic14. 
Furthermore, though in vitro pH-responsive 19F imaging agents have very recently been 
reported27,28, these systems have not yet been rendered responsive to specific biological 
molecules for molecular MRI. Thus, to our knowledge, there are no examples of entirely 
organic, stimuli-responsive, dual-modality MRI/NIR imaging agents for molecular imaging 
applications.
In an effort to design such materials, we were drawn to the unique properties of 
paramagnetic nitroxides. Nitroxides have been extensively studied as metal-free ‘organic 
radical contrast agents’ (ORCAs) for MRI29–32. They typically show minimal toxicity33, 
and they are reduced to diamagnetic hydroxylamines at variable rates in response to 
physiological reducing agents33–35. This feature has been exploited for selective MR 
imaging of redox processes in vivo36–39. The key disadvantages of nitroxides are their low 
relaxivity compared with metals31 and their very rapid in vivo reduction (on the order of 
minutes for most nitroxides)36–39. Nanostructured ORCAs that carry multiple reduction-
resistant nitroxides can potentially overcome these limitations31,32,40–42.
Nitroxides are also well known for their ability to quench excited singlet states through 
catalysis of intersystem crossing43,44. This property has been exploited for the development 
of nitroxide-fluorophore conjugates, where emission from the fluorophore is enhanced upon 
nitroxide reduction. Such molecules have been used for imaging redox processes in 
vitro45–49 and for analysis of oxidation-induced polymer degradation50,51.
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We report here redox-responsive branched-bottlebrush copolymer NPs (ORCAFluors) that 
possesses a high nitroxide density for MRI and an NIR fluorophore for optical imaging. 
Compared with other nitroxide-based MRI agents, ORCAFluors show excellent stability 
towards biological reducing agents and substantial in vitro and in vivo MRI contrast. 
Furthermore, ORCAFluors display compensatory redox behaviour whereby ascorbate-
induced nitroxide reduction leads to the loss of MRI signal and enhanced fluorescence 
emission. To the best of our knowledge, ORCAFluors represent the first entirely organic 
dual-modality imaging system that is suitable for molecular imaging of redox processes in 
vivo using both MRI and NIR optical imaging.
Results
Synthetic strategy
Our ORCAFluor design is based on the branched-bottlebrush polymer architecture52,53. 
Branched-bottlebrush polymers are nanoscopic copolymers with two or more distinct 
functional domains, at least one of which is a polymer, grafted to every repeat unit of a 
polymer backbone. Such polymers can be readily synthesized via Ru-initiated graft-through 
ring-opening metathesis polymerization (ROMP)54 of norbornene-terminated branched 
macromonomers (MMs). The final size and composition of the polymer depends on the size 
and composition of the MM, as well as the ratio of MM to ROMP initiator. For this study, 
we designed two novel poly(ethylene glycol) (PEG)-based MMs (see Supplementary 
Methods for synthetic details): one carries a reduction-resistant spirocyclohexyl nitroxide 
(chex-MM 1, Fig. 1a) that provides in vivo MRI contrast enhancement31,55; the other carries 
Cy5.5 for NIR fluorescence imaging (Cy5.5-MM 2, Fig. 1a). PEG is included in both the 
structures to increase the hydrophilicity of the final NP and provide for extended circulation 
in vivo56. The structure of each MM was confirmed by matrix-assisted laser desorption/
ionization mass spectrometry (Supplementary Fig. 1) and NMR spectroscopy.
We first tested the ROMP of chex-MM in the absence of Cy5.5-MM. A series of nitroxide-
loaded bottlebrush polymers were prepared via exposure of chex-MM to Grubbs 3rd 
generation initiator for 90 min (Fig. 1b). After this time, the reactions were quenched with 
excess ethyl vinyl ether. Gel permeation chromatography (Supplementary Fig. 2) analysis of 
the crude polymerization reactions indicated that the MM conversion was greater than 95% 
for all n values from 13 to 141. These results agree with our previous observations in related 
nitroxide-labelled ROMP polymer systems53,57,58; the graft-through ROMP process is 
extremely efficient. For this range of n values, we expect the particles to display a spherical, 
star-like solution structure. Dynamic light scattering analysis revealed hydrodynamic 
diameters (Supplementary Table 1) that ranged from 13 to 24 nm as n varied from 13 to 141, 
respectively. This range is suitable for systemic in vivo administration; PEGylated particles 
of this size display enhanced circulation times in blood and selective tumour uptake via the 
enhanced permeation and retention effect59.
Characterization of nitroxide-functionalized branched-bottle-brush polymers
Electron paramagnetic resonance (EPR) spectroscopy was used to characterize the spin 
environment and concentration in these polymers. As expected for the branched-bottlebrush 
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polymer architecture with a high nitroxide density near the poly(norbornene) backbone53 
(for example, P1 with n = 54), the EPR spectrum is significantly broader than that of chex-
MM (Fig. 2a). The spin concentrations for all the polymer samples were typically >90%.
Longitudinal (r1) and transverse (r2) relaxivities for chex-MM and this series of branched-
bottlebrush polymers were measured using a Bruker 7T MRI instrument (Supplementary 
Table 1, Supplementary Fig. 3). The r1 and r2 values for chex-MM were 0.21 mM−1 s−1 and 
0.30 mM−1 s−1, respectively. As expected for slowly diffusing NPs5,24, the branched brush 
polymers displayed increased relaxivity values (Supplementary Table 1). For example, the 
values for P1 were r1 = 0.32 mM−1 s−1 and r2 = 0.82 mM−1 s−1, which correspond to 52 and 
173% increases, respectively. The molecular relaxivities of P1 can be obtained by 
multiplying the per nitroxide values by the average number of nitroxides per particle: r1mol = 
15.7 and r2mol = 40.3 for P1. These values are comparable to clinically used metal-based 
contrast agents23; we reasoned they would provide sufficient contrast for in vivo imaging 
applications. A T1-weighted MRI phantom for P1 (10 mM nitroxide in phosphate-buffered 
saline (PBS)) shows a 3.34±0.14-fold enhancement compared with PBS alone (Fig. 2b). 
These relative enhancements are in qualitative agreement with the r1 values, the T1 and T2 1H relaxation times and the parameters used to obtain the phantom images.
Next, we assessed the nitroxide reduction kinetics of these materials in the presence of 
ascorbate. Ascorbate is known to be a major contributor to nitroxide reduction in vivo where 
concentrations range from micro- to millimolar depending on the tissue type34,60,61. This 
reduction is very rapid for most nitroxide derivatives; we hypothesized that the combination 
of the known reduction-resistant spirocyclohexyl nitroxide with the sterically shielded 
branched-bottlebrush architecture would provide enhanced reduction resistance and extend 
the utility of these materials in vivo. The reduction of chex-MM and P1 in response to 
ascorbate (20 equivalents (equiv.) per nitroxide) was monitored by EPR spectroscopy (Fig. 
2c). The quenching results were compared with an analogous 2,2,6,6-tetramethyl-1-
piperidinyloxy (TEMPO)-conjugated branched-bottlebrush polymer53 (Fig. 2c, green) and a 
spirocyclohexyl nitroxideconjugated poly(propylenimine) (PPI) dendrimer (Fig. 2c, red)31. 
As expected, the TEMPO-polymer was reduced very rapidly under these conditions (Fig. 2c, 
green). The macromonomer (Fig. 2c, black) and dendrimer (Fig. 2c, red) showed increased 
reduction resistance due to the spirocyclohexyl nitroxide and the addition of PEG. The 
branched-bottlebrush polymer P1, with spirocyclohexyl nitroxides shielded by PEG at every 
monomer unit, was the least susceptible to reduction (Fig. 2c, blue). These results support 
our hypothesis that the combination of the branched-bottlebrush architecture with the 
reduction-resistant spirocyclohexyl nitroxide will enhance reduction resistance. Note that 
similar initial rate constants for reduction of nitroxides were obtained using ascorbate/
glutathione (Supplementary Table 2).
ORCAFlour synthesis and in vitro analysis
Encouraged by these results with P1, we prepared an analogous ORCAFluor (OF1) via 
copolymerization of 55 equiv. of chex-MM and 1% (0.55 equiv.) Cy5.5-MM (Fig. 1). We 
reasoned that this approach would provide a sufficient amount of Cy5.5 for fluorescence 
imaging with minimal impact on nitroxide density and MRI contrast. GPC analysis of OF1 
(Supplementary Fig. 4) shows a monomodal molar mass distribution with >99% MM 
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conversion. The refractive index and 675 nm absorption traces overlap, which suggests that 
Cy5.5 is successfully incorporated into the polymer. Cryogenic transmission electron 
microscopy imaging of OF1 revealed a spherical morphology with an average diameter of 
19±8 nm (Supplementary Fig. 5); this value agrees closely with the hydrodynamic diameter 
for P1 as measured by dynamic light scattering.
We reasoned that the dense nitroxide backbone of OF1 would quench the Cy5.5 emission 
(Fig. 3a); nitroxide reduction would then lead to decreased MRI contrast and an enhanced 
fluorescence signal. Fluorimetric analysis (Supplementary Figs 6 and 7) of OF1 in the 
absence of ascorbate suggests that Cy5.5 fluorescence is not completely quenched. 
However, when two different samples of OF1 were treated with 60 equiv. of ascorbate, a 
rapid ~120% increase in fluorescence was observed (Fig. 3b, black circles and squares). 
When 30 equiv. (Fig. 3b, black triangles) or 10 equiv. (Fig. 3b, white triangle) were added to 
OF1, the emission intensity increased by ~80% and ~25%, respectively. Addition of another 
30 equiv. or 50 equiv., respectively, to these samples increased the emission to the same 
point as the 60 equiv. sample. The average total emission increase was 119±5% for this 
series of experiments. When a control polymer with 1% Cy5.5 and no nitroxides was 
exposed to 60 equiv. of ascorbate, no significant increase in emission intensity was observed 
(Fig. 3b, grey circles). Furthermore, OF1 showed no significant response to the reducing 
agent glutathione (GSH) alone; addition of ascorbate to a mixture of OF1 and GSH led to a 
250% increase in fluorescence intensity (Fig. 3b, white circles). GSH is known to enhance 
the overall extent of ascorbate-mediated nitroxide quenching via reduction of ascorbate 
radicals that can otherwise re-oxidize newly formed hydroxylamines35,62. Collectively, 
these results strongly suggest that fluorescence enhancement of OF1 occurs selectively in 
response to ascorbate-induced nitroxide reduction. Though this enhancement is not as large 
as observed for small-molecule sensors where the nitroxide is directly coupled to a 
fluorophore44,49, we were encouraged to explore the potential of OF1 for in vivo dual-
modality imaging (vide infra).
Discussion
Before imaging studies, we sought to assess the preliminary toxicity and pharmacokinetic 
properties of OF1. PEGylated ROMP nanostructures typically display low toxicity and 
extended circulation time in vivo63–65. We hypothesized that OF1, which possess a dense 
PEG corona, would behave similarly. In vitro, no discernible toxicity was observed as 
determined by cell viability assays with HeLa cells (ATCC, Supplementary Fig. 8). Little 
gross toxicity was observed in healthy BALB/c mice intravenously administered OF1 doses 
from 1 to 40 mg per mouse (0.04–2 gkg−1); acceptable66,67 (1–10%) body weight decreases 
over the first 5 days after injection were followed by a return to the initial body weight 
within 10 days (Supplementary Fig. 9) and no apparent behavioural changes. Preliminary 
pharmacokinetics data were obtained via fluorescence imaging (IVIS, Cy5.5 λex/λem = 
640/700 nm, Xenogen) of blood samples taken at various time points after an injection of 30 
mg of OF1. An initial rapid clearance was observed (~60% over 30 min), which was 
followed by a slow linear decay from 40 to 20% over 3 days (Supplementary Fig. 10). Note 
that these values are based on comparison to the % of injected fluorescence, which is 
complicated by nitroxide reduction in the blood (vide infra). Nevertheless, the data indicate 
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that a significant fraction of the particle is present in the blood even after 3 days. This 
extended circulation suggests that OF1 could be used in the future for tumour-targeted 
imaging via the enhanced permeation and retention effect59.
In an effort to demonstrate the dual-modality imaging potential of OF1, four NCR nude 
mice were anaesthetized with 1–2% isofluorane and imaged via IVIS and T1-weighted MRI 
(see Supplementary Methods for details). The mice were then systemically administered 
(tail vein) 30 mg of OF1 dissolved in pH 7.4 PBS solution. After 30 min, the mice were 
anaesthetized and imaged by MRI and IVIS. At this point, a blood sample was taken, the 
mice were killed (CO2 chamber), and organs were collected, imaged with IVIS and frozen 
on dry ice.
Figure 4a,b show pre- and 30 min post-OF1 injection MRI images, respectively. Values of 
volume-averaged % contrast enhancement (Fig. 4c) were obtained from region of interest 
(ROI) analysis using ImageJ software. The largest contrast enhancements (145±23% and 
71±13%) were observed in the regions associated with the renal pelvis, renal artery, renal 
vein (labeled green in Fig. 4a,b) and the aorta (labeled red in Fig. 4a,b), respectively. These 
data suggest a high concentration of non-reduced OF1 in the blood, which agrees well with 
the pharmacokinetic data discussed above (Supplementary Fig. 10). These enhancements are 
comparable with the highest reported for entirely organic MRI contrast agents31,32.
The renal medulla and cortex showed a small contrast increase (21±5%), while the brain and 
the liver showed no detectable enhancement. We were particularly surprised by the latter 
result, given that nanoparticles similar in size to OF1 are known to accumulate in the liver56. 
Unlike humans, mice possess the requisite enzyme, gulonolactone oxidase, for ascorbate 
biosynthesis; this process occurs in the liver, where the ascorbate concentration is in the mM 
regime68,69. Thus, we suspected that ascorbate-induced nitroxide reduction in the liver could 
explain the low MRI contrast in this organ. If so, a strong fluorescence signal should be 
observed in the liver.
Figure 5 shows whole-animal fluorescence and ex vivo necropsy IVIS images for the same 
animal imaged via MRI above. Minimal autofluorescence is observed before OF1 injection 
(Fig. 5a); 30 min after injection, the maximum fluorescence is observed in the liver and 
kidneys with a small amount of fluorescence observable in the heart (Fig. 5b). These results 
are corroborated by tissue necropsy data (Fig. 5c,d), which shows the greatest fluorescence 
intensity in the liver and kidneys. We also observed significant fluorescence in the blood 
(Fig. 5d) and lung, the latter of which is saturated with blood. This strong signal in the 
blood, which coincides with the regions of greatest MRI contrast, suggests that the particle 
is indeed present in the blood mostly in a non-reduced state. The observation of maximal 
fluorescence in the liver supports our hypothesis that OF1 accumulates in the liver, but that 
the nitroxides are more reduced in this organ.
To further support these results, EPR spectra of tissue homogenates were obtained for two 
sets of mice killed 30 min and 24 h after OF1 injection (Fig. 6a, Supplementary Fig. 11); 
these data were used to correlate the spin concentration (that is, % injected dose of nitroxide 
per gram of tissue) with fluorescence (that is, % fluorescence of injected dose per gram of 
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tissue) as a function of tissue type and time after injection (Fig. 6b). Statistically significant 
decreases in spin concentration ([spin]) were observed between the 30 min and 24 h time 
points for all organs studied, however, 5.6±0.7% of the injected spin dose remained in the 
blood, whereas only 0.3±0.1% remained in the liver where the ascorbate concentration is 
higher. If a decrease in [spin] were simply due to the changes in biodistribution or excretion 
of the particle, then we would expect a concomitant decrease in fluorescence. For example, 
the kidney showed a marked decrease in fluorescence after 24 h, which suggests that the 
particle does not accumulate in the kidney. In contrast, the liver, brain, heart and blood all 
showed no significant decreases in fluorescence after 24 h, despite the decrease in [spin]. 
After 24 h, we would expect the concentration of OF1 in the blood to decrease significantly; 
the observation of a similar fluorescence at 30 min and 24 h is most likely due to 
fluorescence enhancement in response to nitroxide reduction. Notably, the liver and the 
brain, where the ascorbate concentration is the greatest68, showed the least amount of 
nitroxide after 24 h (none was detectable in the brain tissue), but a significant amount of 
fluorescence. Taken together, these results suggest that there is a correlation between 
ascorbate concentration and OF1 fluorescence, and confirm that the dual-modality nature of 
OF1 can be used to provide complementary information related to redox processes in vivo.
In conclusion, we have demonstrated the synthesis, characterization and preliminary in vivo 
analysis of a new class of entirely organic ascorbate-sensitive dual-modality molecular 
imaging agents. These new ORCAFluors were prepared using graft-through ROMP 
reactions of spirocyclohexyl nitroxide and Cy5.5-conjugated MMs. Exposure of 
ORCAFluor OF1 to ascorbate leads to nitroxide reduction and enhanced fluorescence 
emission. In vivo studies confirmed that OF1 displayed significant MRI contrast 
enhancement (among the highest known for organic MRI contrast agents), as well as 
fluorescence emission that correlates with ascorbate concentration in vitro and in vivo. To 
our knowledge, this work represents the first example of a responsive organic agent for 
dual 1H MRI contrast enhancement and live whole-animal fluorescence imaging. The long 
in vivo circulation of these particles, and their redox-responsive properties, could make them 
applicable for tumour imaging studies. Our modular ORCAFluor design and flexible 
synthetic strategy, which is amenable to incorporation of other functionalities, such as 
drugs70 and cellular targeting agents, make these new particles a promising platform for 
further development as redox-sensitive theranostic agents.
Methods
General methods
Precursor syntheses, reagent information, and in vitro MRI relaxivity quantification are 
detailed in the Supplementary Methods. Please see Supplementary Fig. 12 for PEG-amine 
synthesis setup, Supplementary Figs 13–16 for NMR spectra, and Supplementary Table 3 
for in vivo spin concentration analysis. Instrumentation information can be found in 
Supplementary Note 1. Details of MRI phantom intensity as a function of relaxivity (Fig. 
2b) are provided in Supplementary Note 2.
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General procedure for branched-bottlebrush polymer synthesis by ROMP
All ROMP reactions were conducted following the same general procedure. The 
representative method described below is specific for OF1; polymers with different degrees 
of polymerization can be readily prepared by varying the macromonomer to initiator ratio. 
Note: all polymerizations were performed under nitrogen atmosphere.
Chex-MM (198 mg, 0.05 mmol) and Cy5.5-MM (2.0 mg in 20 μl, 0.5 μmol) were combined 
in a 4 ml vial and dissolved in 0.795 ml tetrahydrofuran. A solution of Grubbs 3rd 
generation bispyridine initiator (0.278 ml of 4 mg ml−1 initiator solution, 1 μmol) was added 
to the vial and the resulting reddish-brown solution was stirred at room temperature for 90 
min. After this time, the reaction was quenched with one drop of ethyl vinyl ether. An 
aliquot of the reaction solution was taken for GPC analysis; the remainder was transferred to 
a 15 kDa molecular weight cutoff dialysis tubing (Spectrum Laboratories) with 5 ml of 
nanopure water. The polymer was dialysed against 500 ml of nanopure water (three rounds 
of fresh water were added with 2 h intervals between each solvent exchange) with gentle 
stirring. The polymer solution was then lyophilized to dryness, and stored in the dark at 4 
°C. GPC traces for OF1 and other representative polymers prior to dialysis are provided in 
Supplementary Figs 2 and 4.
Fluorimetric analyses
Analysis of Cy5.5 fluorescence in various branched-bottlebrush polymer samples was 
performed by monitoring excitation and emission at 640 and 703 nm, respectively. Slit 
widths of 5 nm for excitation and 7 nm for emission were used for all studies. Polymer 
samples (OF1 or control polymer with no nitroxide) were dissolved in 2 ml of pH 7.4 1X 
PBS buffer; ultraviolet/visible and fluorescence spectra were collected. Aliquots of ascorbic 
acid were then added to the cuvette as outlined in Fig. 3b. Emission spectra were repeatedly 
obtained until no change was observed. A representative series of spectra are shown in 
Supplementary Fig. 7. Note: The pH was measured before and after addition of 60 equiv. of 
ascorbic acid; the values were 7.0 and 6.31, respectively. The absorption/emission properties 
of Cy5.5 are not pH dependent.
Kinetics of nitroxide quenching by EPR spectroscopy
The results of kinetic measurements are summarized in Supplementary Table 2. The 
ascorbate solution was made with ascorbic acid, sodium phosphates (<30 p.p.m. transition 
metals), sodium hydroxide and diethylenetriaminepentaacetic acid (DTPA, 0.1% (mol/mol) 
to sodium phosphates) at pH 7.4. This solution was used to dissolve the powder of reduced 
L-glutathione (GSH), providing the ascorbate/GSH solution, as needed. Solutions of the 
agents were prepared in phosphate buffer, which was made from sodium phosphates and 
DTPA (0.1% (mol/mol) to sodium phosphates) at pH 7.4. The kinetic runs were carried out 
in the presence of a 250-fold molar excess of sodium phosphates with a 20-fold molar 
excess of ascorbate (or 20-fold of ascorbate and 10-fold of GSH). Before a typical kinetic 
run, equal volumes of the freshly prepared solution of ascorbate (or ascorbate/GSH) and the 
solution of agent were combined, vortexed for a few seconds and then the resultant mixture 
was drawn into three or four EPR-quality quartz capillary tubes (0.6-mm inner diameter). 
The capillaries were stoppered with parafilm and placed in a 5-mm outer diameter EPR 
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sample tube in the cavity of X-band spectrometer. The peak height of the low-field line of 
the triplet was measured as a function of time. Microwave power was kept under 6.5 mW 
and the temperature was controlled at 295 K with a nitrogen flow system.
Phantom relaxivities by MRI
Monomers and polymers were transferred as solutions in dichloromethane to a set of 
accurately weighed clean vials, and then evacuated to a constant mass in Schlenk containers 
(1 mTorr-vacuum). For selected monomers and polymers, small samples (0.4–0.8 mg) were 
examined by 1H NMR spectroscopy in chloroform-d (500 MHz, cryoprobe, 3-mm tubes); 
only monomer chex-MM had a very small residue of dichloromethane, whereas all the other 
samples were solvent free. To each vial containing the sample, 0.5 mM PBS (0.800 ml, pH 
7.2 checked with pH meter) was added, to provide homogenous-to-turbid stock solutions. 
Spin concentrations of stock solutions were determined by EPR spectroscopy. Serial dilution 
(100–10% in 10% increments) of each stock solution provided an array of ten 0.1-ml-
samples in PCR tubes; for each T1 and T2 measurement of 1H in water, the array of ten 0.1-
ml samples and 0.1-ml sample of buffer (11 PCR tubes) were used. T1 and T2, measured at 
the University of Nebraska Medical Center, were obtained using coronal T1 and T2 map 
imaging protocols (Supplementary Table 1 and Supplementary Fig. 3). T1 mapping was 
done using a progressive saturation RARE T1 mapping measurement with RARE factor = 4, 
First TE and spacing of 6.4 ms, TR = 10,000, 5,000, 3,000, 1,500, 1,200, 800, 500, 450, 400, 
350 and 300 ms, 60 mm field of view, 1 mm slice thickness, one slice for a total acquisition 
time of 10 min. T2 mapping was done using CPMG-phase-cycled multiecho imaging of all 
sample concentrations including buffer in a single image. Acquisition parameters were: 10 
echo, TE = 10 ms, one 1 mm thick slice, 256 × 128 matrix, one average, 3000 ms repetition 
time, 60 mm field of view, for a total acquisition time of 10 min. T1 and T2 values were 
extracted from each sample in the image using ROIs in the image sequence analysis tool in 
Paravision 5.1. T2 values were determined by using the even-numbered echoes, fitting the 
noise floor using the highest free radical concentration and fixing the value for the 
remaining samples in each image.
Cell culture and in vitro toxicity
HeLa cells (ATCC) were maintained in MEM Media supplemented with 1% penicillin/
streptomycin and 10% fetal bovine serum in 5% CO2 humidified atmosphere (37° C). Cells 
were plated in 96-well plates at 10,000 cells per well and grown for 24 h before treating with 
varied concentrations of polymer. Each polymer concentration was represented by four 
replicate wells. After 48 h, the cells were incubated for 4 h with thiazolyl blue tetrazolium 
bromide (MTT). Reduced thiazoyl tetrazolium formazan was then solubilized with dimethyl 
sulfoxide, and cell viability was calculated on the basis of the absorbance at 550 nm.
Animal usage
All procedures involving animals were reviewed and approved by the MIT Committee for 
Animal Care. Toxicity and pharmacokinetics studies were performed on healthy female 
BALB/c mice aged 12–16 weeks. MRI studies were performed on healthy female NCR nude 
mice that received an alfalfa-free diet to minimize autofluorescence. All studies involving 
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animals were performed on groups of n = 4 or n = 5 to provide statistical significance. 
Exclusion criteria included human error in NP administration.
In vivo toxicity and pharmacokinetics
Eight polymer solutions ranging from 0.1–40 mg of OF1 in sterile pH 7.4 PBS buffer were 
prepared. To find an initial toxicity threshold, each solution was administered to one mouse 
per particle solution. NP solutions were passed through a 0.2 micron filter before injection 
via catheter into the tail vein. All of these doses appeared to be well tolerated. Thus, two 
groups of five animals were dosed with 30 or 40 mg of OF1. Animals receiving 40 mg of 
OF1 demonstrated higher weight loss and some initial lethargy, while animals receiving 30 
mg displayed no adverse physical effects; the 30 mg dosage was used for all subsequent 
imaging studies.
In vivo MRI and IVIS
MRI experiments were conducted at the Koch Institute for Integrative Cancer Research at 
MIT using a Varian 7T/310/ASR-whole mouse MRI system. T1-weighted MR images were 
collected using the fast spin echo multiple slices pulse sequence with minimum repetition 
time (TR) = 739 ms, ESP = 9.52 ms, ETL = 4, a 256 × 256 matrix and four averages over 18 
slices at 1 mm thickness. Scans were collected with respiratory gating (PC-SAM version 
6.26 by SA Instruments Inc.) to avoid confounding noise due to chest movement. 
Respiratory rate and animal temperature were closely monitored during image collection.
In vivo fluorescence images were obtained on an IVIS Spectrum bioluminescent and 
fluorescent imaging system from Xenogen. Excitation and emission values (640 nm, 700 
nm, respectively) were kept constant, and exposure times from 2–10 s were used. Epi-
fluorescence is reported in radiant efficiency and used only as comparison between pre- and 
post-injection values.
MRI and IVIS images were obtained for each animal (n = 4) before administration of OF1. 
Mice were fit with tail vein catheters and slowly injected with OF1 solution. Thirty minutes 
or 24 h after injection was complete, the mice were imaged via both IVIS and MRI, and then 
immediately killed in a CO2 chamber for tissue collection and fluorescence imaging (vide 
infra). Organs were briefly washed with saline to remove any exogenous blood from the 
dissection process.
In vivo MRI and IVIS data analysis
ROI around each organ was manually selected for a given image slice. The average intensity 
and area of the ROI were measured. This procedure was repeated for each image slice where 
the organ/tissue was visible. Using Excel (Microsoft), the average intensity of each ROI was 
multiplied by its area. These values were then summed together for all image slices of a 
given organ. This sum was divided by the sum of the ROI areas for the same organ to 
provide the volume-averaged intensity. The same procedure was repeated for images of four 
mice collected before and 30 min after injection of OF1 (eight images total). Volume-
averaged intensity increases (shown in Fig. 4c) were obtained from the following equation: 
((contrast 30 min after injection) − (contrast before injection))/(contrast before injection) × 
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100%. The values for % contrast enhancement were normalized by the muscle, which was 
assumed to be zero. Note that this normalization changed the final values by <10%.
Ex vivo fluorescence methods
After collecting in vivo MRI and fluorescence data (vide supra), mice were killed in a CO2 
chamber and immediately dissected to remove the kidneys, liver, spleen, heart, lungs, brain 
and a section of flank muscle tissue. Organs were quickly washed with PBS buffer to 
remove excess blood from the necropsy process. Extracted organs were placed on a black, 
non-emitting background for fluorescence analysis. IVIS parameters were identical to those 
used for in vivo measurements.
Ex vivo EPR spectroscopy
The animal tissues were shipped in dry ice from MIT to University of Nebraska in 
centrifuge tubes. Upon receipt, the tubes were stored in liquid nitrogen. For preparation of 
EPR samples, the tissues samples were temporarily moved from the liquid nitrogen storage 
to dry ice. Each tissue sample, one at a time, was rapidly thawed, and then transferred to a 
weighed vial. Then, 0–500 μl of PBS buffer (0.5 mM, pH = 7.2) was added. The sample 
with PBS was then put into an ice-water bath and homogenized with a rotor stator 
homogenizer, and then pipetted to a 4-mm outer diameter EPR sample tube. The samples 
were degassed by sonication, as needed (for example, when gas bubbles were visible). The 
EPR tube was capped, sealed with parafilm and then stored briefly in acetone-dry ice bath 
before the measurement of spin concentration.
The spin concentrations of nitroxide radicals in tissues (μmol g−1, μmol of S = ½ nitroxide 
radical per gram of tissue) were measured at −30 °C (243.2 K), to increase signal-to-noise 
for the aqueous samples. Measurements of the tissue samples were alternated with the 
measurements of the references for spin concentration (see next paragraph) and g-value (2,2-
diphenyl-1-picrylhydrazyl powder was used as a g-value reference). For tissue samples with 
low signal-to-noise, the cavity background was recorded with identical parameters as for the 
tissue sample (including identical number of scans and identical receiver gain). Typical 
parameters were as follows: microwave attenuation (20 dB), modulation amplitude (5 
Gauss), spectral width (300 Gauss), resolution (512 points), conversion (40.96), time 
constant (10.24) and sweep time (20.97 s.); these parameters were kept identical for the 
tissues, references and cavity backgrounds. The number of scans (8–256) and receiver gain 
were adjusted as needed for each sample.
The reference for spin concentration was prepared from OF1. The polymer was dissolved in 
PBS (0.5 mM, pH 7.2) to provide 1.036 mM solution, for which concentration was 
calibrated with 3-carboxy-PROXYL in PBS buffer (0.5 mM, pH 7.2) at ambient temperature 
(295.0 K). This reference was always stored in dry ice, except during the measurement, and 
occasionally re-checked for spin concentration decay.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. ORCAFluor precursors and synthetic scheme
(a) Structures of branched macromonomers (MMs) used in this study. (b) General procedure 
for the graft-through ROMP synthesis of ORCAFluor imaging agents. RT, room 
temperature; THF, tetrahydrofuran.
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Figure 2. Properties of nitroxide-loaded branched-bottlebrush polymers
(a) EPR spectra of chex-MM compared with n = 54 bottlebrush polymer P1. (b) MRI 
phantoms and relative contrast enhancements (compared with PBS buffer) of chex-MM and 
P1. (c) Analysis of nitroxide reduction in response to ascorbate. a‘dendrimer’ referes to 
previously reported fourth generation spirocyclohexyl nitroxide-functionalized 
poly(propyleneimine) dendrimer31. b‘TEMPO-polymer’ refers to previously reported 
2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO)-functionalized branched-bottlebrush 
polymers53.
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Figure 3. Redox-sensitive dual-modality imaging mechanism
(a) Schematic for dual-modality molecular imaging in response to nitroxide reduction. (b) 
Emission behaviour of OF1 and a control polymer with Cy5.5 and no nitroxides upon 
exposure to varied amounts of ascorbate or glutathione (GSH) in PBS buffer. The solution 
pH before and after addition of 60 equiv. ascorbic acid was 7.0 and 6.31, respectively; this 
pH change has no affect on Cy5.5 absorbance/emission. equiv., equivalent.
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Figure 4. MRI imaging studies
(a) MR image of whole mouse before OF1 injection with specific organs/tissues outlined for 
reference. Red asterisk: structure labeled as aorta could also include inferior vena cava. 
Green asterisk: structure labeled renal pelvis could also include renal artery and renal vein. 
(b) MR image of the same mouse 30 min after OF1 injection. (c) Quantitative analysis 
(mean±s.e.) of volume-average MR image contrast enhancement for four mice 30 min after 
OF1 injection. The values correlate with [spin] values obtained by EPR (vide Fig. 6).
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Figure 5. NIR fluorescence imaging studies
(a) IVIS image of whole mouse before OF1 injection. (b) IVIS image of the same mouse in 
a 30 min after OF1 injection. (c) Ex vivo IVIS images of organs before OF1 injection. (d) Ex 
vivo IVIS images of organs and blood sample after OF1 injection.
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Figure 6. Ex vivo spin and fluorescence quantification
(a) EPR spectra of blood and homogenized tissue samples. (b) Recovered fluorescence 
intensity and spin concentration in selected tissues. Error bars represent s.e.m. values 
obtained from four and three mice at 30 min and 24 h, respectively. Statistical comparisons 
were made with a student’s t-test: **P<0.01 and ***P<0.001. NS, not significant.
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